SCCM Resource Library-Adjunctive Methylene Blue for Patients in Septic Shock: The SHOCKEM-Blue Trial

Adjunctive Methylene Blue for Patients in Septic Shock: The SHOCKEM-Blue Trial

Video Transcription

Video Summary

Dr. Nuria Yala discusses the results of a trial investigating the use of methylene blue in patients with septic shock. The trial, called the Shock and Blue Trial, is the largest study on this topic in 20 years. The study included 92 patients, with 46 in the intervention group receiving methylene blue and 46 in the control group. The intervention group had a shorter duration of vasopressor use, faster normalization of lactate levels, and shorter ICU stays compared to the control group. The most common side effect was green-blue discoloration of urine. The study suggests that methylene blue may be an effective therapy for septic shock and further research is needed.

Asset Subtitle

Sepsis, Research, 2023

Asset Caption

Type: star research | Star Research Presentations: Pharmacology II (SessionID 30016)

Meta Tag

Content Type Presentation

Knowledge Area Sepsis

Knowledge Area Research

Membership Level Professional

Membership Level Select

Tag Outcomes Research

Tag Shock

Year 2023

Keywords

Dr. Nuria Yala

methylene blue

septic shock

Shock and Blue Trial

vasopressor use

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.